Deoratives Bannerbild

November 2021: Survival analysis of the randomised phase III GeparOcto trial


The survival analysis of the randomized phase III GeparOcto trial has been published in European Journal of Cancer

GeparOcto demonstrated that pathological complete response (pCR) of intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddEPC) was comparable to weekly paclitaxel/non-pegylated liposomal doxorubicin (plus carboplatin (PM(Cb) in triplenegative breast cancer [TNBC]) in high-risk early breast cancer (BC). Here, we report time-to-event secondary endpoints.


  • No significant survival difference was observed for the entire cohort, HER2-positive and triple-negative breast cancer subgroups.
  • Patients with HR-positive/HER2-negative breast cancer benefit from iddEPC despite no difference in pCR rate.

Conclusion: While there was no difference in survival for the entire cohort, the HR+/HER2-subgroup significantly benefits from iddEPC. This supports the concept of an additional effect of NACT beyond pCR in patients with HR+/HER2- BC.

Schneeweiss A, Michel LL, Möbus V, et al. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer. 2022;160:100-111.


GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd